IBD-Associated Arthritis
When the gut and the joints are part of the same picture. The fourth post in our spondyloarthritis series.
This is the fourth post in our spondyloarthritis series. Today is IBD-associated arthritis, or enteropathic arthritis, which occurs in patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis).
Of all the spondyloarthritis subtypes, this is one where coordinated care matters the most. The same immune dysfunction that drives the gut disease can drive joint inflammation, and the treatment decisions often depend on what's happening in both systems at once.
The connection
Joint involvement is one of the most common extra-articular manifestations of inflammatory bowel disease. Roughly 20 to 30% of patients with IBD will develop some form of joint disease over the course of their illness.
In most cases, the IBD comes first or both develop around the same time. Less often, joint symptoms appear before the GI symptoms are recognized, which is one reason rheumatology evaluations can occasionally help unmask undiagnosed IBD.
Two patterns
IBD-associated arthritis usually presents in one of two patterns, and the distinction matters clinically:
Peripheral arthritis. Affects joints in the arms and legs. Usually asymmetric, often involving large joints like the knees and ankles. This pattern tends to track with the activity of the bowel disease. When the gut is flaring, the joints flare. When the gut is well-controlled, the joints often follow.
Axial involvement. Inflammatory back pain and sacroiliitis. Can look identical to ankylosing spondylitis. Importantly, this pattern does not track with bowel disease activity. The spine inflammation has a life of its own.
Some patients have one pattern, some have both. The treatment strategy is shaped by which patterns are present.
Other features
Other things we look for in IBD-associated arthritis:
Enthesitis (tendon insertions, especially the heels)
Dactylitis (the "sausage digit")
Uveitis (sometimes called iritis when only the front of the eye is involved). Inflammation inside the eye that can cause pain, redness, light sensitivity, and blurred vision. Needs prompt evaluation.
Erythema nodosum and other skin findings associated with IBD
Diagnosis
The diagnosis is usually clinical and depends heavily on the context. In a patient with known IBD, joint symptoms with an inflammatory pattern (morning stiffness, swelling, asymmetric large joints, inflammatory back pain) point toward IBD-associated arthritis.
In a patient without an IBD diagnosis, the situation is harder. Joint symptoms can precede the bowel disease by months or years. When I see a young patient with peripheral oligoarthritis or inflammatory back pain along with GI symptoms (chronic diarrhea, abdominal pain, weight loss, blood in stool), I'll often coordinate with GI for a workup.
Labs (including HLA-B27 and inflammatory markers) and imaging are used the same way as in other spondyloarthritis subtypes. The clinical picture is what makes the diagnosis.
Treatment
This is where IBD-associated arthritis has some of the most clinically distinct nuances in the spondyloarthritis family. The treatment decisions are shaped by both the gut and joint disease, and certain medications behave very differently here than they do in the other SpA subtypes.
NSAIDs. Use with caution. They can help joint pain but can also flare bowel disease. In active IBD, I generally try to avoid them.
Sulfasalazine. A useful older agent that can help both joints (peripheral arthritis especially) and mild IBD. Often a good starting point in patients who aren't on biologics yet.
Methotrexate. Effective for the joints. Some role in Crohn's, less so in UC.
TNF inhibitors. First-line biologic class for most patients with significant IBD-associated arthritis. Infliximab (Remicade) and adalimumab (Humira) cover both gut and joints well. Certolizumab (Cimzia) and golimumab (Simponi) also have GI indications. Etanercept (Enbrel) is the exception. Despite being a TNF inhibitor, etanercept doesn't work for IBD, and case data suggest it may even be associated with new-onset IBD in some patients. It's not used in this setting.
IL-12/23 inhibitor. Ustekinumab (Stelara). Approved for both IBD and joint disease. A strong option, especially in Crohn's.
IL-23 inhibitors. Risankizumab (Skyrizi) and guselkumab (Tremfya). Approved for IBD and for psoriatic arthritis, and I use them in IBD-associated arthritis when the overlap calls for it. The dual coverage can be valuable.
JAK inhibitors. Tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are approved for UC and for joint disease. Upadacitinib is now approved for Crohn's as well.
IL-17 inhibitors. Avoided in IBD-associated arthritis. Secukinumab and other IL-17 inhibitors can worsen or trigger IBD, which limits their use in this population even though they're highly effective in other spondyloarthritis subtypes.
A note on vedolizumab
One clinical scenario worth knowing about: vedolizumab (Entyvio) is a gut-selective biologic. It works only in the intestinal tissue and doesn't treat joint disease.
For IBD patients who have well-controlled gut disease and well-controlled joint disease on a systemic biologic like infliximab, switching to vedolizumab can unmask the joint inflammation. The joints were being covered by the previous medication, and once that coverage stops, the joint symptoms can come forward.
The takeaway is that decisions about switching biologics in IBD patients with known or potential joint involvement should ideally involve both rheumatology and GI. We can often anticipate the issue and plan around it.
The bottom line
If you have inflammatory bowel disease and you're dealing with joint pain, swelling, stiffness, or back pain with an inflammatory pattern, the two are often connected. The conditions share treatment options, and coordinated care between GI and rheumatology produces the best outcomes.
If you're being evaluated for unexplained joint symptoms and have GI symptoms that haven't been worked up, mention them. The connection can run in either direction.
